As part of the deal, Thermo Fisher will further offer Horizon’s X-MAN haploid cell line generation service to its worldwide customer base with the exception of Japan.
Horizon’s X-MAN cell line range represents an extensive bank of genetically defined human cell lines, models that accurately exhibit disease-causing genetics, and have undergone a high degree of validation and quality control.
The exclusive distribution agreement for Japan between Horizon and Summit Pharmaceuticals International (SPI) remains unchanged.
According to the company, these models help researchers to understand how complex genetic diseases manifest themselves.
They can also reduce the cost of bringing to market new personalized therapies by streamlining many aspects of drug development, including target identification, target validation, assay development, drug screening, lead optimization and biomarker-driven clinical trial design.
Horizon Discovery Products president Dr Paul Morrill said: "This strategic agreement underscores the value of Horizon’s X-MAN cell line collection and gene editing services, and, in particular, highlights the impact Horizon’s haploid models are already having on the research community, following the acquisition of Haplogen Genomics GmbH in January 2015.
"Under this agreement, Thermo Fisher will market these products to researchers worldwide using its e-commerce and direct sales channels."